{"entity":{"id":"nct05956587","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other","aka":[],"tldr":"A phase 2 trial of Izalontamab brengitecan in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT05956587 by Sichuan Baili Pharmaceutical Co., Ltd., with 121 participants planned, started 2024-01-29 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, SI-B003. Conditions listed: Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05956587","url":"https://clinicaltrials.gov/study/NCT05956587"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","nasopharyngeal"],"sections":[],"technologies":[],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05956587","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":121,"outcomes":[]},"route":"/trials/nct05956587/","neighbours":{"cancer":[{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}